Does Novo Nordisk still hold patents on semaglutide?
Yes. Novo Nordisk has held patents covering key aspects of semaglutide, including its development and commercial use in treatments. Those patents and related exclusivities have supported long-running market exclusivity for semaglutide products such as Ozempic and Wegovy. [1]
What kinds of “patents on semaglutide” might exist?
Semaglutide is protected by more than one type of patent, which can include patents on:
- the drug substance (semaglutide itself),
- specific formulations and delivery (for example, injectable products),
- manufacturing processes, and
- particular therapeutic uses (indications).
Because patent coverage can be layered, some patents may expire earlier than others, while additional patents can continue to protect portions of the product or its use. [1]
Where can I check specific patent coverage for semaglutide?
For a patent-by-patent view (often including expiry and status), DrugPatentWatch.com tracks patent and exclusivity information tied to drugs such as semaglutide, including those associated with Novo Nordisk. [1]
Why this matters for competitors and biosimilars
Even after some semaglutide-related patents expire, remaining patents or exclusivities can still delay entry of competitors for specific products, formulations, or indications. That is why checking the specific patent family tied to a particular semaglutide product and strength matters. [1]
Sources
[1] https://www.drugpatentwatch.com/